Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Lung adenocarcinoma is the most prevalent form of lung cancer.
• Personalized medicine has emerged due to targeted therapies for EGFR mutations and ALK rearrangements.
• Identifying specific molecular aberrations is crucial for tailoring treatments.

Purpose of the Study:

• To review potential additional molecular targets in lung adenocarcinoma.
• To discuss novel therapeutic strategies for lung adenocarcinoma.
• To highlight the expanding possibilities for personalized therapy.

Main Methods:

• Review of current literature on lung adenocarcinoma targets and therapies.
• Categorization of targets by cellular location (cell surface, intracellular, nuclear) and pathways.
• Discussion of tumor environment pathways.

Main Results:

• Identified key cell surface targets: EGFR, HER2, RET, ROS1, MET, TRK.
• Highlighted intracellular targets: ALK, RAS-RAF-MEK, PI3K-AKT-PTEN, WNT.
• Included nuclear targets: PARP, HSP90, HDAC, and tumor environment pathways.

Conclusions:

• The identification of molecular aberrations is rapidly expanding treatment personalization for lung adenocarcinoma.
• Novel therapies targeting diverse pathways offer new hope for patients.
• Continued research into molecular targets will further refine personalized treatment strategies.